share_log

Longeveron Shares Move Slightly Higher; Co. Issues PR Highlighting News From Friday The Company Was Granted Orphan Drug Designation By FDA For Lomecel-B To Treat Infants With Hypoplastic Left Heart Syndrome

Longeveron Shares Move Slightly Higher; Co. Issues PR Highlighting News From Friday The Company Was Granted Orphan Drug Designation By FDA For Lomecel-B To Treat Infants With Hypoplastic Left Heart Syndrome

Longeveron公司股價小幅走高;公司發佈公關消息週五消息該公司獲得FDA授予的Lomecel-B孤兒藥物指定,用於治療患有左心發育不良綜合徵的嬰兒
Benzinga Real-time News ·  2021/12/06 08:11

Longeveron Shares Move Slightly Higher; Co. Issues PR Highlighting News From Friday The Company Was Granted Orphan Drug Designation By FDA For Lomecel-B To Treat Infants With Hypoplastic Left Heart Syndrome

Longeveron公司股價小幅走高;公司發佈公關消息週五消息該公司獲得FDA授予的Lomecel-B孤兒藥物指定,用於治療患有左心發育不良綜合徵的嬰兒

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論